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ABSTRACT
Zinc-finger nucleases (ZFNs) have been successfully
used for rational genome engineering in a variety
of cell types and organisms. ZFNs consist of a
non-specific FokI endonuclease domain and a
specific zinc-finger DNA-binding domain. Because
the catalytic domain must dimerize to become
active, two ZFN subunits are typically assembled at
the cleavage site. The generation of obligate
heterodimeric ZFNs was shown to significantly
reduce ZFN-associated cytotoxicity in single-site
genome editing strategies. To further expand the ap-
plication range of ZFNs, we employed a combination
ofinsilico proteinmodeling, invitro cleavage assays,
and in vivo recombination assays to identify autono-
mous ZFN pairs that lack cross-reactivity between
each other. In the context of ZFNs designed to
recognize two adjacent sites in the human HOXB13
locus, we demonstrate that two autonomous
ZFN pairs can be directed simultaneously to two
different sites to induce a chromosomal deletion
in  10% of alleles. Notably, the autonomous
ZFN pair induced a targeted chromosomal deletion
with the same efficacy as previously published
obligate heterodimeric ZFNs but with significantly
less toxicity. These results demonstrate that autono-
mous ZFNs will prove useful in targeted genome
engineering approaches wherever an applica-
tion requires the expression of two distinct
ZFN pairs.
INTRODUCTION
Methods to introduce precise and stable modiﬁcations in
complex genomes hold great potential not only for the
study of gene function but also for biotechnological and
therapeutical applications. A promising approach for
rational genome engineering is based on the zinc-ﬁnger
nuclease (ZFN) technology (1–3). ZFNs are artiﬁcial
proteins that consist of a non-speciﬁc endonuclease
domain, derived from the FokI restriction enzyme, and
a speciﬁc DNA-binding domain, which consists of
tandem repeats of engineered zinc-ﬁnger domains, each
mediating binding to  3nt of DNA (4,5). Because the
catalytic FokI domain has to dimerize to become active,
two ZFN subunits are assembled at a cleavage site (6).
Typically, a ZFN subunit contains three or four
zinc-ﬁnger motifs that together recognize 9 or 12bp, re-
spectively. The combined target site is hence deﬁned by a
stretch of 18 or 24bp, a sequence of sufﬁcient length to be
statistically unique in a complex genome.
Several reports have highlighted the power of ZFNs for
studying biological systems in mammalian cells (7,8) or
whole organisms, like the fruit ﬂy (9), nematodes (10),
zebraﬁsh (11–13) or rats (14,15). Moreover, the high fre-
quency of gene editing at endogenous loci in plant cells
(16–19), in mammalian cells classically used for drug
screening or protein production (20–22), or in primary
human cells, including pluripotent stem cells (23–26),
have demonstrated the wide application range of the
ZFN technology in biology, biotechnology or human
gene therapy.
Genome engineering by ZFNs is based on the enzyme’s
ability to activate the cellular DNA repair machinery by
creating a DNA double-strand break in the target locus.
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ZFNs are used to stimulate homologous recombination
(HR) between the target locus and the donor DNA.
In the absence of a donor DNA, cleavage by ZFNs is
harnessed to disrupt a gene locus through the non-
homologous end-joining (NHEJ) pathway (2,3). Very
recently, the ability to create a targeted deletion in a
chromosome by simultaneous expression of two ZFN
pairs has been reported (21,27).
Despite these successes, ZFN-induced toxicity by
cleavage at off-target sites has remained an important
issue (27–29). ZFN variants that combine high activity
with reduced toxicity have been generated by improving
the DNA-binding speciﬁcities of the zinc-ﬁnger domains
(16,30), by customizing the interdomain linkers (31,32),
and/or by regulating the DNA-cleavage activity through
re-design of the FokI protein–protein interface (33,34). In
the latter case, the ZFN dimer interface was altered such
that only heterodimeric ZFNs could form upon binding to
DNA. Here, we extend this approach and report the iden-
tiﬁcation and characterization of ZFN variants that
permit the simultaneous expression of two pairs of
obligate heterodimers, whose monomeric ZFNs do not
cross-react with each other. This technological advance-
ment is relevant for rational genome engineering
approaches that are based on the concomitant expression
of two ZFN pairs, such as targeted chromosomal deletions
or editing the genome at two sites in parallel. We demon-
strate that the combined expression of two autonomous
ZFN pairs was as effective at inducing a chromosomal
deletion as previously described obligate heterodimeric
ZFNs but that preventing cross-reaction between the in-
dividual ZFN subunits reduced toxicity signiﬁcantly.
MATERIALS AND METHODS
In silico analysis
Protein modeling of the FokI cleavage domain was done
with DeepView v4.0 (http://www.expasy.org/spdbv/)
(34,35). Energy calculations of the FokI dimers were per-
formed using FoldX version 3.0beta (http://foldx.crg
.es/references.jsp). The energy function includes terms
that have been found to be important for protein stability,
including Van-der-Waals forces, intra- and inter-
molecular hydrogen-bond formation, electrostatic contri-
butions of charged groups, solvation energy and salt con-
centration. Details are described elsewhere (34,36,37).
Plasmids
The zinc-ﬁnger DNA-binding domains contained in our
ZFN expression plasmids were described previously
(16,30,38). Vectors encoding ZFNs EB2-N and BA1-N,
donor plasmid pUC.Zgfp, target plasmids
pCMV.LacZsXXqGFP (XX referring to the respective
binding sites for BA1-N and/or EB2-N) have been
described earlier (30,39). Lentiviral vector plasmid
pLV-CMV.LacZsEBBAqGFPiNwpre was generated
by replacing the ‘3/1’ target site in pLV-
CMV.LacZs31qGFPiNwpre (40) by the ‘EB/BA’ target
site 50- tCACTGCGGCattaatGCAGAAGCCg (capital
letters indicated binding sites for EB2-N and BA1-N,
respectively). The ZFN expression cassettes for the
HOXB13-speciﬁc ZFNs were generated by releasing the
zinc-ﬁnger domains from the OPEN selection plasmids
(16) with XbaI/BamHI and then ligating them into
the ‘2-in-1’ plasmid in either the ﬁrst position with
NheI/BglII or the second position with XbaI/BamHI.
The ‘2-in-1’ ZFN cassette is under control of a CMV
promoter, and each ZFN contains a triple FLAG tag.
The ZFN subunits are separated by a sequence encoding
the T2A autoproteinase (Figure 4b for more details).
Mutations in the FokI domain were introduced using
site-directed mutagenesis. The relevant sequences are
indicated in Figures 1a, 3a and Supplementary Figure S2.
In vitro cleavage assay
ZFNs were expressed in vitro using the TNT SP6 Quick
Coupled Transcription/Translation System according to
the manufacturer’s instructions (Promega). To verify
equal expression levels, ZFNs were initially synthesized
in the presence of L-[
35S]-methionine, separated by SDS–
PAGE, and detected by autoradiography. The target
DNA fragment was generated by PCR with Pfu polymer-
ase (Stratagene) using plasmids pCMV.LacZsXXqGFP as
templates and primers 50-tgcaccgctggataacgacat and
50-gaacttcagggtcagcttgc (Euroﬁns MWG Operon) to
amplify a 980-bp fragment. A target site for the restriction
enzyme AgeI was located next to the ZFN target site and
used as a positive control. For in vitro cleavage, 1mlo f
each TNT lysate containing one ZFN subunit was mixed
with 200ng of the DNA template, 1mg of BSA and
NEBuffer 4 (50mM potassium acetate, 20mM Tris-
acetate pH 7.9, 10mM magnesium acetate, 1mM
dithiothreitol; New England Biolabs) in a total volume
of 10ml. Where indicated, 100mM NaCl was added to
the reaction. After incubation at 37 C for 90min the
reaction was analyzed on a 1.2% agarose gel.
Quantitative cell-based recombination and toxicity assays
Human HEK293T cells and the HEK293-based target cell
line 293EBBA were grown in DMEM (Gibco/Invitrogen)
supplemented with 10% fetal calf serum (Gibco/
Invitrogen). The polyclonal target cell line 293EBBA
was generated by lentiviral transduction as previously
described (40). To ensure that cells carry a single copy
target, transduction was performed with an MOI <0.1.
The quantitative chromosomal recombination and
toxicity assays were performed as previously described
(40). Brieﬂy, cell line 293EBBA contains an integrated
mutated EGFP target locus (qEGFP) with an adjacent
heterodimeric target site for ZFN subunits EB2-N and
BA1-N (EB/BA). Five days after transfection with the
ZFN expression vectors, a donor plasmid to rescue
EGFP expression by HR and a DsRed-Express (REx) ex-
pression vector, the percentage of green and red cells was
determined by ﬂow cytometry. The percentage of green
cells at Day 5 speciﬁes the frequency of HR, while the
relative decline in the number of red cells from Day 2 to
Day 5 is a marker of ZFN-induced cytotoxicity. The
extent of gene targeting is indicated as percentage of
8270 Nucleic Acids Research, 2010,Vol.38, No. 22EGFP-positive cells normalized for transfection efﬁciency.
The cell survival frequency is indicated as the fraction of
REx-positive cells at day ﬁve as compared to Day 2 after
transfection, normalized to a control transfection with a
mutated nuclease.
Immunoblotting
Immunoblotting was basically performed as previously
described (32). ZFNs were detected with antibodies
directed against the HA tag (NB600-363; Novus
Biologicals) or the FLAG tag (DYKDDDK tag
antibody, Cell Signaling Technology), co-expressed
EGFP with antibody MAB3580 (Millipore). Proteins
were visualized by infrared imaging after incubation
with secondary antibodies conjugated with either
IR-Dyes 680 or 800CW (LI-COR Biosciences).
Genotyping by PCR
200000 HEK293T or 100000 HeLa cells were seeded
in 6-well plates 18h before polyethyleneimine
(PEI)-mediated transfection. The transfection mix con-
tained 1.6mg of each HOXB13-speciﬁc ZFN expression
plasmid, 0.1mg of pEGFP (Clontech) and pUC118 to
5mg in PEI (0.1 g/l, pH 5.5) and 150mM NaCl.
Typically, >80% of cells were transfected as judged by
ﬂow cytometric measurement of EGFP-positive cells.
Genomic DNA from transfected cells was extracted with
the Blood MiniKit (Qiagen) and subsequent PCR analysis
was performed with Phusion High-Fidelity DNA
Polymerase (Finnzymes) in HF buffer using primers
50-ggatggagccaaggatatcgaag and 50-actgtccacaggcaacagg
gagt (Euroﬁns MWG Operon). The PCR products were
separated on a 1.2% agarose gel and quantiﬁed from non-
saturated gel images with Quantity One V.4.6.5 software
(Biorad).
Statistical analysis
All experiments were performed at least four times. Error
bars represent standard deviation and statistical signiﬁ-
cance was determined using a one-sided, unpaired
Student’s t-test with unequal variance.
RESULTS
In vitro characterization of obligate heterodimeric ZFNs
An in-depth analysis of enzymatic reactions often requires
the cumbersome production and puriﬁcation of the indi-
vidual components. Here, we used a simple in vitro tran-
scription/translation system to generate small amounts
of the nucleases for further in vitro characterization.
Previously published ZFN dimerization variants
(Figure 1a, Supplementary Figure S1); (33,34) were
fused to well-characterized zinc-ﬁnger DNA-binding
domains, termed BA1 and EB2 (30), synthesized in vitro
(Figure 1b), and incubated with a PCR generated target
DNA to assess their cleavage activity (Figure 1c). When
using a DNA fragment with a target site for both subunits,
the variant ZFN pairs displayed a similar cleavage activity
as ZFNs with the wild-type FokI domain (Figure 1d, top
panel). However, as opposed to the wild-type ZFN pair,
none of the variant pairs was able to cleave DNA frag-
ments with an inverted repeat target, i.e. where one
subunit has to bind as a homodimer (Figure 1d, lower
panels). This conﬁrms that these three variant ZFNs act
as true obligate heterodimers in vitro.
Identiﬁcation of autonomous ZFN pairs
In order to identify obligate heterodimeric ZFN pairs that
do not cross-react with each other, we performed extensive
in silico analysis. DeepView was used to generate struc-
tural models of the various combinations of the FokI
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Figure 1. In vitro cleavage assay with obligate heterodimeric ZFNs.
(a) Sequence of the FokI variants. The sequence is indicated for FokI
positions 480–490 (helix a4), 499 and 538, and is shown for wild-type
(W) and variants (A, B, C). The two-letter code on the right deﬁnes the
corresponding point mutations in each subunit. (b) In vitro translated
ZFNs. ZFNs were expressed in the presence of
35S-met, separated by
SDS–PAGE and exposed to X-ray ﬁlm. L, left ZFN subunit EB2-N; R,
right ZFN subunit BA1-N. (c) Schematic representation of in vitro
cleavage assay. A linear DNA substrate containing the combined
target site for ZFN subunits EB2-N and BA1-N (EB/BA) or inverted
repeat target sites for subunits EB2-N (EB/EB) or BA1-N (BA/BA),
respectively, are cleaved into different size products. (d) Analysis of
heterodimeric or homodimeric cleavage reactions. A linear DNA sub-
strate was incubated with in vitro translated ZFNs and the extent of
cleavage analyzed by agarose gel electrophoresis. Control reactions
were incubations with in vitro translated EGFP (mock) or AgeI (cto).
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dimerization energies by FoldX at two different salt con-
centrations (Figure 2a). The in silico analysis predicted
that ‘opposite’ ZFN pairs consisting of subunits that
harbor FokI variants from pairs B and C should be
active (dimerization energies similar to the wild-type con-
ﬁguration), while any combination between ZFN subunits
from pairs A and B or pairs A and C, respectively, are not
(positive dimerization energy). As shown in Figure 2b,
these predictions could be veriﬁed using the in vitro
cleavage assay. It is not surprising that ZFN combinations
between variants from pairs B and C were still active
because the respective FokI domains vary at only one
amino acid position (Figure 1a). However, any combin-
ation of ZFN subunits from pairs A and B or pairs A and
C, respectively, did not cleave the DNA target. The same
ZFN combinations were tested further in a previously
described cellular recombination assay (30,34), which is
based on the rescue of a mutant EGFP gene. As
ZFN-mediated cleavage of the chromosomally integrated,
mutated reporter gene stimulates HR with a corrective
donor DNA, the percentage of EGFP-positive cells
reﬂects the activity of the respective ZFN combinations
(Figure 2c). Transfection of the human HEK293-based
reporter cell line with expression plasmids for ZFN
variant pairs B/B and C/C revealed a decrease in the per-
centage of EGFP-positive cells as compared to wild-type
ZFN, suggesting some attenuation due to the altered
dimer interface. As seen in vitro, ZFN pairs B/C and
C/B interacted with each other and supported correction
of the mutant EGFP gene. Transfection of any combin-
ation of ZFN subunits from pairs A and B or pairs A and
C, respectively, showed no substantial activity. However,
ZFN pair A/A revealed only little activity compared to
wild-type, suggesting that this variant is strongly
attenuated. This signiﬁcant drop in activity is likely a
function of the considerable increase in the dimerization
energy (Figure 2a) and not of the protein-expression level
(Figure 2d). To further test this hypothesis, we repeated
the in vitro cleavage assay using a higher salt concentra-
tion (Figure 2e). When adding 100mM NaCl to the
reaction, ZFN variant A/A was not able to cleave the
DNA, substantiating that the lower cleavage activity is
due to highly attenuated dimerization.
The FokI single amino acid exchange variant pair
D483R/R487D is similar to pair A but lacks the addition-
al mutations that destabilize the hydrophobic interaction
(Figure 3a). We and others have previously shown that
D483R/R487D, here termed pair 0, is an obligate
heterodimer (8,12,33,34). In silico examination predicted
that ZFN pair 0 should be more active than pair A and
that the ‘0’ subunits should not interact with ZFN
subunits from pairs B and C (Figure 3b). These
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Figure 2. Comprehensive analysis of obligate heterodimeric ZFNs.
(a) In silico computation of dimerization energy. The interaction
energy of two variant ZFN subunits was calculated using FoldX
based on structural models created with DeepView. The table indicates
the average of the two calculated values (in kJ/mol) obtained when
computing left-right versus right–left. (b) In vitro cleavage assay. A
linear DNA substrate containing the heterodimeric target site for
subunits EB2-N (L) and BA1-N (R) was incubated with in vitro
translated ZFN variants in different combinations and the extent of
cleavage analyzed by agarose gel electrophoresis. Control reactions
were incubations with in vitro translated EGFP (mock) or wild-type
ZFN (W). (c) Chromosomal recombination assay. Cell line 293EBBA
contains an integrated mutated EGFP target locus (qEGFP) with an
adjacent heterodimeric target site for ZFN subunits EB2-N and BA1-N
(EB/BA). After transfection with the various ZFN expression vectors
and a donor plasmid, the percentage of EGFP-positive cells was
assessed by ﬂow cytometry. An expression vector encoding a mutated
nuclease (mock) was included as a control to indicate the level of
non-stimulated gene targeting. A statistically signiﬁcant (P<0.005)
decrease in gene targeting between homologous and heterologous
ZFN subunit combinations is indicated by asterisks. (d) ZFN expres-
sion levels. Transfected HEK293T cells were harvested after 30 h and
lysates probed with an antibody against the HA tag. ‘mock’ indicates
transfection with an EGFP-expression vector. (e) Sensitivity to high
salt concentrations. The linear DNA target was incubated with the
in vitro translated variant ZFN pairs and the extent of cleavage
analyzed by agarose gel electrophoresis. (+) or (–) indicates the
presence or absence of an additional 100mM NaCl in the reaction.
Control reactions were incubations with in vitro translated EGFP
(mock) or AgeI (cto). A, B, C, and W denote FokI variants as
deﬁned in Figure 1a.
8272 Nucleic Acids Research, 2010,Vol.38, No. 22predictions were veriﬁed by in vitro cleavage assays. ZFN
pair 0 was active under high salt concentrations (Figure
3c, upper panel) and the respective subunits did not form
active ZFNs when combined with the subunits of pairs B
and C (Figure 3c, lower panel). These observations were
conﬁrmed in the cellular EGFP rescue assay, which
indicated that none of the tested combinations, except
pair 0/0, stimulated HR (Figure 3d). A comparison with
combinations B/B and C/C revealed that ZFN variant 0/0
showed similar activity in HEK293 cells (compare to
Figure 2c). To evaluate the ZFN-associated toxicity of
these variants, cells were transfected with high amounts
of the corresponding ZFN expression plasmids and
spiked with an EGFP vector. Relative survival of cells,
as determined by ﬂow cytometry in comparison to cells
transfected with a control expression plasmid, revealed
that all obligate heterodimeric ZFN variants induced
signiﬁcantly less cytotoxicity than wild-type ZFN
(Figure 3e). Together, this panel of in silico, in vitro and
in cellula results indicates that all variant ZFN pairs—with
the exception of variant A—combine high activity with a
signiﬁcantly lower ZFN-associated toxicity. Moreover,
these data suggest that ZFN variant 0 does not cross-react
with variant pairs B and C.
Application of autonomously functioning ZFN pairs to
targeted chromosomal deletion
In order to demonstrate that autonomously dimeric ZFN
pairs have an advantage over cross-reacting pairs, we
evaluated these variants for their use in creating a
targeted chromosomal deletion in human cells. To this
end, different combinations of variant FokI domains
were fused to zinc-ﬁnger DNA-binding domains that
target two sites in exon 1 of the human HOXB13 locus
(16; Figure 4a and b, Supplementary Figure S2a).
Immunoblotting revealed that the steady state levels of
all ZFN constructs were similar (Figure 4c). Two days
after transfecting HEK293T or HeLa cells with different
combinations of these variant ZFNs, genomic DNA was
extracted and exon 1 ampliﬁed by PCR (Figure 4d,
Supplementary Figure S2b). The percentage of alleles
that revealed deletions was  10% for both cross-reacting
(combination hx1/hx2 or hx6/hx7) and autonomous ZFN
variants (combination hx1/hx3 or hx6/hx3) in either cell
line. Clonal analysis of HEK293T cells transfected with
hx1/hx3 followed by PCR-based genotyping revealed
that 9 out of 59 analyzed clones harbored a deleted
allele (Supplementary Figure S2c), thus verifying the
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Figure 3. Identiﬁcation of autonomous ZFN variants. (a) Sequence of
the FokI variant pair 0. The sequence is indicated for FokI positions
480–490 (helix a4), 499 and 538. The two-letter code on the right
deﬁnes the corresponding point mutation in each subunit. (b) In silico
computation of dimerization energy. The table indicates the average of
the two calculated values (in kJ/mol) obtained when computing left–
right versus right–left. (c) In vitro cleavage assays. A linear DNA sub-
strate was incubated with in vitro translated ZFNs and the extent of
cleavage analyzed by agarose gel electrophoresis. Top: the linear DNA
target was incubated with variant ZFN pair 0. (+) or (–) indicates the
presence or absence of an additional 100mM NaCl in the reaction.
Bottom: subunits of variant 0 were combined with the respective
subunits of variants B and C. Control reactions were incubations
with in vitro translated EGFP (mock), wild-type ZFN (W) or AgeI
(cto). (d) Chromosomal recombination assay. Target cell line
293EBBA was transfected as in (Figure 2c) with combinations of the
various ZFN expression vectors. The columns designate the percentage
of EGFP-positive cells 5 days after transfection, as determined by ﬂow
cytometry. An expression vector encoding a mutated nuclease (mock)
was included as a negative control. A statistically signiﬁcant (P<0.002)
decrease in gene targeting between homologous and heterologous ZFN
subunit combinations is indicated by asterisks. (e) Quantitative cyto-
toxicity assay. HEK293 cells were transfected as described in (d). The
columns represent the fraction of DsRed-Express-positive cells at day 5
as compared to the fraction at Day 2 after transfection, and are shown
relative to transfection with an expression vector encoding a mutated
nuclease (mock). A statistically signiﬁcant increase in cell survival as
compared to wild-type ZFN (W) is indicated by (*P<0.01). A, B, C, 0
and W denote FokI variants.
Nucleic Acids Research, 2010,Vol.38, No. 22 8273calculated deletion frequency from Figure 4d.
Importantly, expression of ZFN combination hx4/hx5
did not induce a detectable amount of chromosomal
deletion. This demonstrates that the FokI variants 0 and
B do not cross-react with each other although the
zinc-ﬁnger domains mediate binding to the two target
sites. Sequence analysis of HOXB13 alleles harboring
the ZFN-induced deletion conﬁrmed that the deletions
are NHEJ-mediated fusions between the two ZFN half-
sites at positions HX587 and HX761 (Supplementary
Figure S2d). However, a cold shock—very recently
shown to increase ZFN-mediated mutagenesis (41)—did
not augment ZFN-mediated chromosomal deletion in
either cell line (data not shown). Assessment of
ZFN-associated cytotoxicity (Figure 4e) revealed that
cell survival is signiﬁcantly improved when comparing
cross-reacting obligate heterodimeric ZFNs (hx1/hx2 or
hx6/hx7, respectively) versus the autonomous ZFN pairs
(hx1/hx3 or hx6/hx3, respectively). Taken together, these
results show the advantage of employing autonomous
ZFN pairs over cross-reacting ZFN pairs for the
purpose of inducing a targeted chromosomal deletion in
two different cell lines.
DISCUSSION
Toxicity upon expression of a single pair of ZFNs in
human cells has been associated with off-target cleavage
activity (8,23,28), the creation of unintentional chromo-
somal deletions (27), chromosomal instability at triplet
repeats (42), and more generally, with apoptosis (39) and
cell death (16,30,32–34,43). It seems therefore obvious that
expression of two ZFN pairs in a single cell will further
exacerbate these problems. If one were to use the wild-type
FokI dimer interface on four ZFN monomers, this would
lead to 12 possible dimeric permutations, which deﬁne 10
unique target sites. Even if one uses obligate heterodimeric
FokI domains, four different pairs can form, all of which
have the potential to induce DSBs at off-target loci. One
potential solution to this problem is to generate ZFN pairs
that do not cross-react with each other, so-called autono-
mous ZFN pairs. In this report, we describe the identiﬁ-
cation and characterization of two autonomous
heterodimeric FokI domain pairs that we show can be
utilized to induce a targeted chromosomal deletion. We
demonstrate that the combined expression of two autono-
mous ZFN pairs that target adjacent sites in the human
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Figure 4. Targeted chromosomal deletion in human HOXB13 locus.
(a) Diagram of genomic PCR strategy. ZFN target sites (HX587 and
HX761) and possible PCR products are indicated. (b) Schematic rep-
resentation of HOXB13-speciﬁc ZFN expression constructs. Each ex-
pression plasmid encodes two ZFN subunits, which are separated by a
sequence encoding the T2A autoproteinase. The plasmid names are
shown on the left, the speciﬁcity of the DNA-binding domain and
the respective FokI variant is indicated in the boxes. The FokI conﬁg-
uration of the ﬁve tested combinations at the two target sites is shown
on the right. (c) ZFN expression levels. Lysates of HEK293T, which
were co-transfected with ZFN expression vectors and pEGFP, were
probed with antibodies against the FLAG tag and EGFP. Mock
indicates transfection with empty vectors. (d) Targeted chromosomal
deletion. HEK293T were transfected with pEGFP and the indicated
plasmids. PCR was performed on extracted genomic DNA and frag-
ments separated by agarose gel electrophoresis. The size of the frag-
ments is indicated on the right. Mock indicates transfection with a
mutant nuclease and gDNA denotes a non-transfected control
sample. (e) Quantitative cytotoxicity assay. HEK293T cells were trans-
fected as described in (d). The columns represent the average fraction
of EGFP-positive cells at Day 5 as compared to the fraction at Day 2
after transfection, and are shown relative to transfection with an ex-
pression vector encoding a mutated nuclease (mock). A statistically
signiﬁcant increase in cell survival between combinations hx1/hx2 and
hx1/hx3 or hx6/hx7 and hx6/hx3 is indicated by (*P<0.05). B, C and 0
denote FokI variants.
8274 Nucleic Acids Research, 2010,Vol.38, No. 22HOXB13 locus was as effective at inducing a chromosom-
al deletion as published obligate heterodimeric ZFN
variants. Importantly, however, preventing cross-reaction
between the individual ZFN subunits reduced toxicity
signiﬁcantly.
To identify pairs of autonomous ZFNs, we applied in
silico protein modeling and energy calculations to charac-
terize different combinations of variant FokI dimer inter-
faces. As reported previously (34), these computational
analyses are a powerful tool to predict protein–protein
interactions and, as established here, to predict the
activity of ZFNs. The calculated energy threshold for ef-
ﬁcient dimerization of ZFNs seems to be in the range of
 2kJ/mol. Any combination with a higher value turned
out to be inactive in the in vitro cleavage assay or the
cellular recombination assay. It should be noted that all
variant FokI domains tested here showed a  30%
decrease in activity as compared to the wild-type conﬁg-
uration. However, the additional gain in speciﬁcity—as
displayed e.g. by reduced toxicity—clearly outweighs this
drop in activity.
We would like to point out a seeming discrepancy
between the results obtained in this study and results
published earlier (34), in which we reported that a ZFN
with FokI variant A (RV/DA) worked more efﬁciently
than ZFNs with variants B (KV/EA) or 0 (DD/RR). As
recently reported (28), the zinc-ﬁnger DNA binding
domains used in Szczepek et al. had a low speciﬁcity for
their binding sites, as directly shown by their activity
at off-target sites and indirectly demonstrated by the
induction of massive cytotoxicity and apoptosis at even
low ZFN concentrations (34,39). This is in agreement
with the ﬁndings that the speciﬁcity of DNA-binding of
a ZFN correlates with both its activity at the target site
and reduced ZFN-associated toxicity (30). We believe that
the high toxicity associated with the ZFN in Szczepek
et al. obscured the readout for ZFN activity. A high
nuclease activity (as in DD/RR) in combination with
low DNA-binding speciﬁcity will induce massive cell
death and therefore reduce the number of targeted cells
in the population, while a ZFN variant with a highly
attenuated nuclease activity (as in RV/DA) will induce
less cytotoxicity and therefore seemingly increase the
number of targeted cells. In conclusion, the actual contri-
bution of the FokI domain to activity and toxicity of
a ZFN can only be delineated when using zinc-ﬁnger
domains with optimized DNA-binding parameters,
such as zinc-ﬁnger arrays generated using the OPEN
protocol (16).
In summary, autonomous ZFNs have a major advan-
tage over simple obligate heterodimeric ZFNs, wherever
an application requires the expression of two distinct ZFN
pairs. It is safe to assume that the signiﬁcant improvement
in ZFN-associated toxicity, as measured in the trans-
formed HEK293T cell line, is much more pronounced
in sensitive primary cells and that the observed decrease
in toxicity is based on reduced ZFN cleavage at off-target
sites by preventing cross-reaction between the distinct
ZFN pairs. Major applications of autonomous ZFN
pairs will include the introduction of targeted chromo-
somal deletions (27) or forced translocations (44) to
answer biological questions. Founded on the improved
safety proﬁle, we also foresee applications in human
gene therapy. For example, analogous to morpholino-
induced therapeutic exon skipping for muscular dystro-
phy, ZFN-induced deletion of the mutation-containing
exons could restore the open reading frame of
dystrophin (45).
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